Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05112614 · ClinicalTrials.gov registry record
Role of Gut Microbiome in Cancer Therapy
A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 3
- Study locations
NCT05112614: Recruiting study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by Mayo Clinic.
NCT05112614 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 3,000 participants, above the 1,124-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (167% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05112614, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body. Information from this study may help doctors improve the way cancer treatment is delivered, and increase its effectiveness and success.
Primary Outcome
Will be done using Shogun pipeline for metagenomics data followed by analysis using Quantitative Insights Into Microbial Ecology (QIIME) 2.0.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
Study Locations (3)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2019-09-11 |
| Est. Completion | 2030-10-01 |
What NCT05112614 shows while recruiting
NCT05112614 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,124-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (167% higher).
The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT05112614 reports a single indexed study location in Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05112614 about?
NCT05112614 is a clinical study titled "Role of Gut Microbiome in Cancer Therapy". This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body. Information from this study may help doctors improve the way cancer treatme...
What is the current status of trial NCT05112614?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2019-09-11. Estimated completion is 2030-10-01.
What conditions does trial NCT05112614 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm.
What interventions are being tested in trial NCT05112614?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT05112614?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05112614 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05112614's enrollment target sits among peer trials
3,000 11th of 176 higher than 166 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
RECRUITING
-
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
Voices: Messages of Wisdom and Hope in the Face of Illness
RECRUITING
-
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI